CME Information

Up to 3 AMA PRA Category 1 Credit(s)™

Release date: February 2009        Valid through: February 2010

Course Material: Online Only

Receiving CME Credit

To receive online CME credit for this activity, read the full activity then click below to complete the post-test and evaluation.  You will be able to print your CME certificate immediately following completion of the post-test and evaluation.

CME Test and Evaluation

Target Audience
This educational activity is intended for medical, surgical, and radiation oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.

Educational Objectives
Following completion of this activity, participants should be able to:

• Assess efficacy and safety considerations for using approved EGFR inhibitor therapies in lung cancer.
• Discuss why some initially responsive patients may become resistant to EGFR inhibitor therapy.
• List 3 approaches to overcoming resistance to EGFR inhibitors.
• Assess appropriate role for anti-EGFR monoclonal antibody-based therapy in NSCLC.
• Discuss optimal means of patient selection for first and subsequent-line use of anti-EGFR-based therapies in lung cancer.

Educational Need
Agents targeting the epidermal growth factor receptor (EGFR) have shown dramatic efficacy in a subset of patients with non–small cell lung cancer and have been shown in some circumstances to improve outcomes for larger groups of patients. It is now recognized, however, that patients whose cancer initially responds to these inhibitors eventually acquire resistance to such therapy. Recent research provides important insights for patient treatment. Oncologists who assess, treat, and counsel lung cancer patients need to be aware of important new data on EGFR inhibitor response and resistance, new EGFR inhibitors in development, and current recommendations for lung cancer treatment.

Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.

Educational Grant Support
Supported by educational grants provided by Genentech, Bristol-Myers Squibb and ImClone Systems, Inc., and Pfizer, Inc.

Credit Designation
InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Financial Disclosure
The program faculty disclosed the following financial relationships: Walter J. Curran: Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, ImClone. Jeffrey A. Engelman: Consultant: Aveo, Bristol-Myers Squibb, Millennium, Novartis, OSI. Giuseppe Giaccone: Nothing to disclose. Roy S. Herbst: Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, ImClone, Pfizer, sanofi-aventis; Speakers’ Bureau: Eli Lilly, Genentech. David M. Jackman: Consultant: Genentech; Honoraria: Roche. Bruce E. Johnson: Consultant: Genzyme; Patents: Genzyme for EGFR testing; Royalties: Genzyme for EGFR testing patent. Corey J. Langer: Research Funding: Active Biotech, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Cell Therapeutics, Eli Lilly, Genentech, ImClone, Medimmune, OrthoBiotech, OSI, Pfizer, sanofi-aventis, Schering-Plough, Vertex; Scientific Advisor: Abbott, Abraxis, Amgen, AstraZeneca, Bayer/Onyx, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, ImClone, Intrabiotics, Novartis, Pharmacyclics, Pfizer, sanofi-aventis, Savient; Speakers’ Bureau: Bristol-Myers Squibb, Eli Lilly, Genentech, ImClone, OrthoBiotech, OSI, sanofi-aventis. Thomas J. Lynch: Consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Hoffman-La Roche, ImClone, Millennium, OSI, sanofi-aventis, Serono; Patents: Genzyme for EGFR testing; Royalties: Genzyme for EGFR testing patent. Vincent A. Miller: Consultant: Boehringer Ingelheim, Genentech, Genmab, ImClone, OSI; Honoraria: Boehringer Ingelheim, Genentech, Genmab, Imclone, OSI; Patents: Molecular MD for EGFR testing; Royalties: Molecular MD. William Pao: Patents: Molecular MD for EGFR testing. Lecia V. Sequist: Research Funding: AstraZeneca, Genentech, Infinity. Jeffrey Settleman: Consultant: Celgene, Epizyme; Honoraria: Biogen, Ensai, Vertex; Research Funding: AstraZeneca, EntreMed, Novartis; Royalties: Genzyme. InforMEDical staff who contributed to planning and editing content, and individuals who provided independent peer review, have no financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, contradictions and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.

NEXT > >